SKLB 610 T1895
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, at the concentration of 10 _M in biochemical kinase assays.
CAS nr:
1125780-41-7
Purity:
98%
Molecular Weight:
415,37
SMILES:
CNC(=O)c1nccc(Oc2ccc(NC(=O)c3cc(ccc3)C(F)(F)F)cc2)c1
Formula:
C21H16F3N3O3
Pathway:
Angiogenesis,Tyrosine Kinase/Adaptors,Tyrosine Kinase/Adaptors,Angiogenesis,Tyrosine Kinase/Adaptors,Angiogenesis
Target:
PDGFR,PDGFR,VEGFR,VEGFR,FGFR,FGFR
